COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Cancer|Ovarian Cancer|Breast Cancer|Lung Cancer|Endometrial Cancer|Ovarian Neoplasm|Triple Negative Breast Cancer|Lung Neoplasm|Neoplasm Malignant|Colo-rectal Cancer
Interventions: DRUG: COM701|DRUG: COM701 with Opdivo (Nivolumab).
Sponsor: Compugen Ltd
Collaborators: Bristol-Myers Squibb